Wegovy® Tablets
Wegovy® tablets are a once-daily oral semaglutide treatment for weight management in suitable adults.
No injection pen is needed. Treatment starts at a low daily dose and increases gradually, subject to prescriber assessment, suitability and tolerance.
- No injections
- Once-daily tablet
- Prescription-only medicine
- Clinical review required before supply
- 30 days supply per order
Important: The dose you select is subject to prescriber approval. Your prescriber may change or decline treatment if it is not clinically appropriate.
Wegovy® tablets are usually started at 1.5 mg once daily for 1 month, then increased to 4 mg, then 9 mg, before stabilising on 25 mg once daily from month 4, subject to prescriber approval and tolerability.
Following the gradual dose increase gives the treatment the best chance of working effectively while helping manage side effects.
The higher-strength tablets (4 mg, 9 mg and 25 mg) are expected to become available later this month. We will remove the out-of-stock banner as soon as each dose is available to order.
If you are starting on the 1.5 mg starter dose now, your prescriber will guide your step-up to the higher strengths once stock arrives.
Price range: £95.00 through £164.00
| Options available | Price |
|---|---|
| 1.5mg | £95.00 |
| 4mg | £97.00 Out of Stock |
| 9mg | £114.00 Out of Stock |
| 25mg | £164.00 Out of Stock |
Select option after consultation.
If you're ordering anything other than the starter dose and haven't received your last dose from DoToR, you'll need to upload evidence of your previous order.
It's a quick and simple step—so no need to worry!
FAQs about weight loss tablet medications
Everything you need to know about the product. Can’t find the answer you’re looking for? Please chat to our friendly team.
Wegovy® tablets contain semaglutide, a GLP-1 medicine used for weight management in suitable adults.
They are taken by mouth once daily and offer an alternative for people who prefer not to use weekly injections.
Wegovy® tablets are prescription-only medicines. Supply is subject to an online consultation, clinical suitability, stock availability and prescriber approval.
References :
- MHRA / GOV.UK announcement — UK approval of semaglutide tablets for weight management
Used for: UK approval, indication, dosing schedule, “empty stomach / 8 hours fasting / wait 30 minutes” instructions, and private Wegovy injection 2.4 mg to 25 mg tablet switching note. - eMC / medicines.org.uk — Wegovy tablets Summary of Product Characteristics
Used for: professional clinical wording, BMI criteria, dose escalation, one-tablet-per-day rule, switching from Wegovy 2.4 mg injection to 25 mg tablets, administration instructions, interactions, pregnancy/breast-feeding and safety warnings. - eMC / medicines.org.uk — Wegovy tablets Patient Information Leaflet
Used for: patient-friendly explanation of how to take the tablet, dose schedule, missed dose advice, pregnancy/contraception warning, common side effects, and “do not split/crush/chew” wording. - Wharton et al., New England Journal of Medicine — Oral semaglutide 25 mg in adults with overweight or obesity / OASIS 4
Used for: clinical efficacy data for oral semaglutide 25 mg. The trial reported greater mean weight loss with oral semaglutide 25 mg than placebo at 64 weeks and more GI side effects than placebo. - ClinicalTrials.gov — OASIS 4 trial record, NCT05564117
Used for: trial design/background confirmation for the oral semaglutide 25 mg weight-management study.



